MO-TRANS: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase III Study of Mocravimod (MOC) As Adjunctive and Maintenance Treatment in AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Blood

Topics

Biology

Cancer Oncology

Medicine

Pathology

Internal Medicine

Show all topics

DOI

10.1182/blood-2024-203080